Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 2/2009

01.08.2009 | Original Article

Polycystic ovary syndrome and fibrocystic breast disease: is there any association?

verfasst von: Ilknur Inegol Gumus, Asli Koktener, Dilek Dogan, Nilgun Ozturk Turhan

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

We aimed to investigate the association between a polycystic ovary syndrome (PCOS) and fibrocystic breast disease.

Methods

A total of 93 women, aged between 17 and 36 years, not using oral contraceptives, were entered ın this case-control study. Laboratory, clinical and ultrasound findings were used to diagnose PCOS. The study group was consisted of 53 PCOS women and the control group consisted of 40 women. Breast ultrasonography was performed for all patients. Fibrocystic breast disease is described as common benign changes involving the tissues of the breast.

Results

Twenty-one (39.6%) of 53 women with a PCOS had fibrocystic breast disease. Five (8%) of 40 controls had fibrocystic breast disease. The difference between the groups was statistically significant (p = 0.004). Relative risk (95% CIs) was 3.17 (1.31–7.68). Overall sonographic benign breast pathologies were significantly higher in the PCOS group (p = 0.036).

Conclusion

This study showed a statistically significant association between a PCOS and fibrocystic breast disease. Women with a PCOS should be evaluated for fibrocystic breast disease.
Literatur
3.
Zurück zum Zitat Lobo RA, Carmina E (2000) The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 132:989–993PubMed Lobo RA, Carmina E (2000) The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 132:989–993PubMed
4.
Zurück zum Zitat Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF (2000) A prospective study of the prevalenceof the polycystic ovary syndrome in unselected Caucasianwomen from Spain. J Clin Endocrinol Metab 85:2434–2438. doi:10.1210/jc.85.7.2434 PubMedCrossRef Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF (2000) A prospective study of the prevalenceof the polycystic ovary syndrome in unselected Caucasianwomen from Spain. J Clin Endocrinol Metab 85:2434–2438. doi:10.​1210/​jc.​85.​7.​2434 PubMedCrossRef
6.
Zurück zum Zitat The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2003) Revised consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47. doi:10.1093/humrep/deh098 CrossRef The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2003) Revised consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47. doi:10.​1093/​humrep/​deh098 CrossRef
7.
Zurück zum Zitat Gorins A, Denis C (1995) Effects of progesterone and progestational hormones on the mammary gland. Arch Anat Cytol Pathol 43:28–35PubMed Gorins A, Denis C (1995) Effects of progesterone and progestational hormones on the mammary gland. Arch Anat Cytol Pathol 43:28–35PubMed
8.
Zurück zum Zitat Thalaband JC, Sitruk-Ware R, Kuttenn F, Mauvais-Jarvis P (1986) Endocrine markers in benign breast diseases. Zentralbl Gynakol 108:354–358 Thalaband JC, Sitruk-Ware R, Kuttenn F, Mauvais-Jarvis P (1986) Endocrine markers in benign breast diseases. Zentralbl Gynakol 108:354–358
9.
Zurück zum Zitat D’Amelio R, Farris M, Grande S, Feraudo E, Iuliano A, Zichella L (2001) Association between polycystic ovary and fibrocystic breast disease. Gynecol Obstet Invest 51:134–137. doi:10.1159/000052909 PubMedCrossRef D’Amelio R, Farris M, Grande S, Feraudo E, Iuliano A, Zichella L (2001) Association between polycystic ovary and fibrocystic breast disease. Gynecol Obstet Invest 51:134–137. doi:10.​1159/​000052909 PubMedCrossRef
12.
Zurück zum Zitat Lobo RA (1995) A disorder without identiy: ‘HCA’, ‘PCO’, ‘PCOD’, ‘PCOS’, ‘SLS’. What are we to call it? Fertil Steril 63:1158–1160PubMed Lobo RA (1995) A disorder without identiy: ‘HCA’, ‘PCO’, ‘PCOD’, ‘PCOS’, ‘SLS’. What are we to call it? Fertil Steril 63:1158–1160PubMed
13.
Zurück zum Zitat Devit J (1981) Clinical benign disorders of the breast and carcinoma of the breast. Surg Gynecol Obstet 152:437–440 Devit J (1981) Clinical benign disorders of the breast and carcinoma of the breast. Surg Gynecol Obstet 152:437–440
14.
Zurück zum Zitat Feig SA (1989) The role of ultrasound in a breast imaging center. Semin Ultrasound CT MR 10:90–105PubMed Feig SA (1989) The role of ultrasound in a breast imaging center. Semin Ultrasound CT MR 10:90–105PubMed
15.
Zurück zum Zitat Hilton SVW, Leopold GR, Olson LK et al (1986) Real-time breast sonography: application in 300 consecutive patients. AJR 147:479–486PubMed Hilton SVW, Leopold GR, Olson LK et al (1986) Real-time breast sonography: application in 300 consecutive patients. AJR 147:479–486PubMed
16.
Zurück zum Zitat Anderson KE, Sellers TA, Chen PL, Rich SS, Hong CP, Folsom AR (1997) Association of Stein–Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer 79:494–499. doi:10.1002/(SICI)1097-0142(19970201)79:3<494::AID-CNCR10>3.0.CO;2-ZPubMedCrossRef Anderson KE, Sellers TA, Chen PL, Rich SS, Hong CP, Folsom AR (1997) Association of Stein–Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer 79:494–499. doi:10.1002/(SICI)1097-0142(19970201)79:3<494::AID-CNCR10>3.0.CO;2-ZPubMedCrossRef
17.
Zurück zum Zitat Mauvais-Jarvis P Sitruk-Ware R, Kutten F, Sterkers N (1979) Luteal phase insufficiency: a common pathophysiological factor in development of benign and malignant breast disease. In: Bulbrook RD, Taylor DJ (eds) Commentaries on research in breast disease, Alan R. Liss, New York, pp 25–29 Mauvais-Jarvis P Sitruk-Ware R, Kutten F, Sterkers N (1979) Luteal phase insufficiency: a common pathophysiological factor in development of benign and malignant breast disease. In: Bulbrook RD, Taylor DJ (eds) Commentaries on research in breast disease, Alan R. Liss, New York, pp 25–29
19.
Zurück zum Zitat Sitruk-Ware LR, Sterkers N, Mowszowics I, Mauvais-Jarvis P (1977) Inaequate corpus luteal function in women with benign breast disease. J Clin Endocrinol Metab 44:771PubMedCrossRef Sitruk-Ware LR, Sterkers N, Mowszowics I, Mauvais-Jarvis P (1977) Inaequate corpus luteal function in women with benign breast disease. J Clin Endocrinol Metab 44:771PubMedCrossRef
20.
Zurück zum Zitat Torris R, Parodi S, Fontana V, Pensa F, Casella C, Barreca A, De Palo G, Costa A, Decensi A (1998) Effects of fenretinine on plasma IGF-1 and IGFBP-3 in early breast cancer patients. Int J Cancer 76:787–790. doi:10.1002/(SICI)1097-0215(19980610)76:6<787::AID-IJC3>3.0.CO;2-U Torris R, Parodi S, Fontana V, Pensa F, Casella C, Barreca A, De Palo G, Costa A, Decensi A (1998) Effects of fenretinine on plasma IGF-1 and IGFBP-3 in early breast cancer patients. Int J Cancer 76:787–790. doi:10.1002/(SICI)1097-0215(19980610)76:6<787::AID-IJC3>3.0.CO;2-U
21.
Zurück zum Zitat Gebauer G, Jager W, Lang N (1998) mRNA expression of components of the insulin-like growth factor system in breast cell lines, tissues and metastatic breast cancer cells. Anticancer Res 18:1991–1995 Gebauer G, Jager W, Lang N (1998) mRNA expression of components of the insulin-like growth factor system in breast cell lines, tissues and metastatic breast cancer cells. Anticancer Res 18:1991–1995
22.
Zurück zum Zitat Ng EH, Ji CY, Tan PH, Lin V, Soo KC, Lee KO (1998) Altered serum levels of insulin-like growth-factor binding protein in breast cancer patients. Ann Surg Oncol 5:194–201. doi:10.1007/BF02303854 PubMedCrossRef Ng EH, Ji CY, Tan PH, Lin V, Soo KC, Lee KO (1998) Altered serum levels of insulin-like growth-factor binding protein in breast cancer patients. Ann Surg Oncol 5:194–201. doi:10.​1007/​BF02303854 PubMedCrossRef
25.
Zurück zum Zitat Lefebvre J (1997) The protein of fibrocystic breast disease-methods of measurement and clinical implications. Bull Acad Natl Med 181:1487–1500PubMed Lefebvre J (1997) The protein of fibrocystic breast disease-methods of measurement and clinical implications. Bull Acad Natl Med 181:1487–1500PubMed
26.
Zurück zum Zitat Thalaband JC, Sitruk-Ware R, Kuttenn F, Mauvais-Jarvis P (1986) Endocrine markers in benign breast diseases. Zentralbl Gynakol 108:354–358 Thalaband JC, Sitruk-Ware R, Kuttenn F, Mauvais-Jarvis P (1986) Endocrine markers in benign breast diseases. Zentralbl Gynakol 108:354–358
27.
29.
Zurück zum Zitat D’Amelio R, Farris M, Grande S, Feraudo E, Iuliano A (2000) Incidence of fibrocystic disease of the breast in women with polycystic ovary. Clinico-instrumental study. Minerva Ginecol 52:321–325PubMed D’Amelio R, Farris M, Grande S, Feraudo E, Iuliano A (2000) Incidence of fibrocystic disease of the breast in women with polycystic ovary. Clinico-instrumental study. Minerva Ginecol 52:321–325PubMed
33.
Zurück zum Zitat Gammon MD, Thompson WD (1991) Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 134:818–824PubMed Gammon MD, Thompson WD (1991) Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 134:818–824PubMed
34.
Zurück zum Zitat Anderson KE, Sellers TA, Chen PL, Rich SS, Hong CP, Folsom AR (1997) Association of Stein–Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer 79:494–499. doi:10.1002/(SICI)1097-0142(19970201)79:3<494::AID-CNCR10>3.0.CO;2-ZPubMedCrossRef Anderson KE, Sellers TA, Chen PL, Rich SS, Hong CP, Folsom AR (1997) Association of Stein–Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer 79:494–499. doi:10.1002/(SICI)1097-0142(19970201)79:3<494::AID-CNCR10>3.0.CO;2-ZPubMedCrossRef
37.
38.
Zurück zum Zitat Wong YC, Xie B (2001) The role of androgens in mammary carcinogenesis. Ital J Anat Embryol 106:111–125PubMed Wong YC, Xie B (2001) The role of androgens in mammary carcinogenesis. Ital J Anat Embryol 106:111–125PubMed
Metadaten
Titel
Polycystic ovary syndrome and fibrocystic breast disease: is there any association?
verfasst von
Ilknur Inegol Gumus
Asli Koktener
Dilek Dogan
Nilgun Ozturk Turhan
Publikationsdatum
01.08.2009
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 2/2009
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-008-0889-8

Weitere Artikel der Ausgabe 2/2009

Archives of Gynecology and Obstetrics 2/2009 Zur Ausgabe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.